<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sun Pharmaceutical Industries Limited — News on 6ix</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited</link>
<description>Latest news and press releases for Sun Pharmaceutical Industries Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sat, 28 Mar 2026 01:11:33 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sun-pharmaceutical-industries-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364f8978dffbe2df154f52.webp</url>
<title>Sun Pharmaceutical Industries Limited</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited</link>
</image>
<item>
<title>Press Release Mar 27 2026</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-mar-27-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-mar-27-2026</guid>
<pubDate>Sat, 28 Mar 2026 01:11:33 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting".</description>
</item>
<item>
<title>Press Release Mar 21 2026</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-mar-21-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-mar-21-2026</guid>
<pubDate>Sat, 21 Mar 2026 15:57:26 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India".</description>
</item>
<item>
<title>Press Release Mar 16 2026</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-mar-16-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-mar-16-2026</guid>
<pubDate>Mon, 16 Mar 2026 20:23:49 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis".</description>
</item>
<item>
<title>Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumyar-tildrakizumab-asmn-for-the-treatment-of-adults-with-active-psoriatic-arthritis</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-us-fda-acceptance-of-supplemental-biologics-license-sbla-application-for-ilumyar-tildrakizumab-asmn-for-the-treatment-of-adults-with-active-psoriatic-arthritis</guid>
<pubDate>Mon, 16 Mar 2026 11:00:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for ILUMYA for the treatment of adults with active psoriatic arthritis. The FDA regulatory action date for this sBLA is expected by October 29, 2026.</description>
</item>
<item>
<title>Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-showcases-data-across-its-dermatology-and-immunology-portfolio-at-2026-winter-clinical-miami</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-showcases-data-across-its-dermatology-and-immunology-portfolio-at-2026-winter-clinical-miami</guid>
<pubDate>Fri, 27 Feb 2026 15:24:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will share 19 abstracts, including new clinical data, across its dermatology and immunology portfolio, at 2026 Winter Clinical Miami on February 27-March 1, 2026 in Aventura, Florida. The data presentations will include study results for several medications, including ILUMYA® (tildrakizumab-a</description>
</item>
<item>
<title>U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/us-patent-office-issues-final-written-decision-finding-all-challenged-claims-of-sun-pharmas-patent-11697028-to-be-unpatentable-1</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/us-patent-office-issues-final-written-decision-finding-all-challenged-claims-of-sun-pharmas-patent-11697028-to-be-unpatentable-1</guid>
<pubDate>Thu, 26 Feb 2026 14:15:00 GMT</pubDate>
<description>WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.’s U.S. Patent No. 11,697,028 (the “’028 Patent”) to be unpatentable. As previously disclosed in Biofronter</description>
</item>
<item>
<title>Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-introduces-sunday-highlighting-the-everyday-realities-of-skin-cancer-care</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-introduces-sunday-highlighting-the-everyday-realities-of-skin-cancer-care</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) today announced "SUNday," a skin cancer awareness campaign rooted in the idea that "Every Day is SUNday." The phrase reflects the belief that support, education, and connection should be available whenever they're needed—not just at certain moments in time—and underscores Sun Pharma's commitment to working alongside the s</description>
</item>
<item>
<title>Press Release Jan 23 2026</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-jan-23-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-jan-23-2026-5</guid>
<pubDate>Fri, 23 Jan 2026 13:21:54 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated January 23, 2026, titled Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management, .</description>
</item>
<item>
<title>Press Release Jan 15 2026</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-jan-15-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-jan-15-2026-1</guid>
<pubDate>Fri, 16 Jan 2026 03:57:48 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated January 15, 2026</description>
</item>
<item>
<title>Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-the-availability-of-unloxcyttm-cosibelimab-ipdl-for-advanced-cutaneous-squamous-cell-carcinoma-acscc</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-the-availability-of-unloxcyttm-cosibelimab-ipdl-for-advanced-cutaneous-squamous-cell-carcinoma-acscc</guid>
<pubDate>Thu, 15 Jan 2026 19:07:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced UNLOXCYT™ (cosibelimab-ipdl) is now available in the U.S. for healthcare professionals to prescribe for adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation.</description>
</item>
<item>
<title>ILUMYA® (tildrakizumab) Pen (Auto-Injector) Now Available for Canadians Living with Moderate-to-Severe Plaque Psoriasis</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/ilumya-tildrakizumab-pen-auto-injector-135500986</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/ilumya-tildrakizumab-pen-auto-injector-135500986</guid>
<pubDate>Wed, 07 Jan 2026 13:55:00 GMT</pubDate>
<description>Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to announce the availability of ILUMYA (tildrakizumab) Pen, a self-administered auto-injector treatment option for adults living with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</description>
</item>
<item>
<title>Press Release Dec 01 2025</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-dec-01-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-dec-01-2025-2</guid>
<pubDate>Mon, 01 Dec 2025 14:08:08 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Sun Pharma introduces its global innovative drug, Ilumya® inIndia for treatment of moderate-to-severe Plaque Psoriasis".</description>
</item>
<item>
<title>Press Release Nov 26 2025</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-nov-26-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-nov-26-2025-1</guid>
<pubDate>Wed, 26 Nov 2025 13:54:39 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 26, 2025</description>
</item>
<item>
<title>FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/fda-approves-label-update-for-unloxcyttm-cosibelimab-ipdl-based-on-longer-term-data-that-demonstrated-improved-clinical-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma-acscc</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/fda-approves-label-update-for-unloxcyttm-cosibelimab-ipdl-based-on-longer-term-data-that-demonstrated-improved-clinical-outcomes-in-advanced-cutaneous-squamous-cell-carcinoma-acscc</guid>
<pubDate>Wed, 26 Nov 2025 03:51:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the U.S. Food and Drug Administration (FDA) approved an updated label for UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or curative radiation. The updated label now incorporates long-term follow-up data</description>
</item>
<item>
<title>Press Release Nov 17 2025</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-nov-17-2025-3</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-nov-17-2025-3</guid>
<pubDate>Mon, 17 Nov 2025 21:02:20 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India".</description>
</item>
<item>
<title>Press Release Nov 12 2025</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-nov-12-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-nov-12-2025-1</guid>
<pubDate>Wed, 12 Nov 2025 21:04:10 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release</description>
</item>
<item>
<title>Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-canada-inc-acquires-commercial-rights-to-levulanr-kerastickr</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-canada-inc-acquires-commercial-rights-to-levulanr-kerastickr</guid>
<pubDate>Wed, 12 Nov 2025 14:26:00 GMT</pubDate>
<description>Sun Pharma, a global pharmaceutical company with a growing portfolio of Innovative Medicines, today announced it acquired, at no cost, the commercial sales rights to LEVULAN KERASTICK (aminolevulinic acid hydrochloride) in Canada from Clarion Medical Technologies. LEVULAN KERASTICK, a Photodynamic therapy (PDT) treatment for non-hyperkeratotic actinic keratoses (AKs) of the face and scalp,i has been a trusted treatment option for over 20 years, offering more than 4 million people globallyii a pr</description>
</item>
<item>
<title>Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-jeremy-allen-as-vice-president-corporate-affairs-for-north-america</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-jeremy-allen-as-vice-president-corporate-affairs-for-north-america</guid>
<pubDate>Wed, 22 Oct 2025 15:00:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced the appointment of Jeremy Allen as Vice President, Corporate Affairs for North America. In this newly created position, Jeremy will lead Sun Pharma's Government Affairs, Public Policy, Advocacy and Communications across the U.S. and Canada.</description>
</item>
<item>
<title>Press Release Jul 21 2025</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-jul-21-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/press-release-jul-21-2025-1</guid>
<pubDate>Mon, 21 Jul 2025 12:26:08 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release, titled Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint.</description>
</item>
<item>
<title>Sun Pharma Announces Appointment of Richard Ascroft as CEO North America</title>
<link>https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-appointment-of-richard-ascroft-as-ceo-north-america</link>
<guid isPermaLink="true">https://6ix.com/company/sun-pharmaceutical-industries-limited/news/sun-pharma-announces-appointment-of-richard-ascroft-as-ceo-north-america</guid>
<pubDate>Wed, 25 Jun 2025 18:00:00 GMT</pubDate>
<description>Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced the appointment of Richard Ascroft as its new North America Chief Executive Officer (CEO), effective June 16, 2025. Richard brings over three decades of experience in the pharmaceutical industry, with a proven record of leadership, innovation, and strategic growth.</description>
</item>
</channel>
</rss>